Hong Kong to Resume BioNTech Shots Monday After Defect Scare
- Those who missed second shot to be prioritized in rebooking
- Public confidence in city’s vaccine rollout further damaged
A staff member assists a person at a closed vaccination center in Hong Kong on March 24.
Photographer: Kyle Lam/BloombergThis article is for subscribers only.
Hong Kong will resume administering BioNTech SE Covid shots on Monday after authorities concluded that the recent emergence of defective vials didn’t pose a safety risk, capping a 12-day halt that’s further damaged confidence in the city’s dismal vaccine rollout.
The more than 180,000 residents who missed their appointments for first and second doses during the suspension will be rescheduled, with those slated to receive second shots to be given slots within the first few days of resumption, said Secretary for the Civil Service Patrick Nip in a Thursday briefing.